Judith Kulich and Ben Hohn pose the high priority questions that those teams opting to move forward with a launch, or to move forward after a delay, in the face of the COVID-19 pandemic.
Judith Kulich
Advertisement
Articles by Judith Kulich
Pharmaceutical Executive
Three product launch trends driven by emerging biopharma.
Advertisement
Latest Updated Articles
Is the Tail Wagging the Dog in Drug Market Entry?January 13th 2020
Adapting Biopharma Launches in the COVID-19 LandscapeApril 7th 2020
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5